The study’s small size limits interpretation, but it remains the largest real-world data available, experts said.

Substantial savings opportunities exist by using lower-cost biologics for patients with plaque psoriasis, according to one ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

IL-5 inhibitors lead to dramatic reductions in eosinophil levels within 3 days in five patients with drug reaction with ...

Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for ...

Recent advances in molecular and pathobiology have brought the field of dermatology to the cusp of reaching a goal that ...

In the Phase III SELECT-GCA trial, Rinvoq (upadacitinib) 15 mg with a 26-week glucocorticoid taper significantly improved ...

We also assess the rationale for clinical trials of IL-1 inhibitors aimed at preserving β-cell functional mass in patients with new-onset T1DM.

Italfarmaco S.p.A., Cinisello Balsamo, Italy.

AbbVie Inc.'s Q1 earnings highlight an 8.4% revenue boost, driven by Skyrizi & Rinvoq. Click for ABBV's market expansion, ...

most commonly drugs that target the interleukin-1 (IL-1) pathway including anakinra (Kineret) and canakinumab (Ilaris) -- unlike in other forms of inflammatory arthritis in which tumor necrosis factor ...

MediLink Therapeutics (Suzhou) Co., Ltd., Suzhou, China.